Non-alcoholic fatty liver disease (NAFLD) has emerged as the most prevalent liver disease
in the world, yet there are still no approved pharmacological therapies to prevent or treat this …

Our understanding of nonalcoholic fatty liver disease pathophysiology continues to advance
rapidly. Accordingly, the field has moved from describing the clinical phenotype through the …

The increasing epidemic of obesity worldwide is linked to serious health effects, including
increased prevalence of type 2 diabetes mellitus, cardiovascular disease and nonalcoholic …

Peroxisome proliferator–activated receptor α (PPAR α) is a nuclear receptor of clinical
interest as a drug target in various metabolic disorders. PPAR α also exhibits marked anti …

NAFLD is closely linked with hepatic insulin resistance. Accumulation of hepatic
diacylglycerol activates PKC-ε, impairing insulin receptor activation and insulin-stimulated …

Background & Aims Elafibranor is an agonist of the peroxisome proliferator− activated
receptor-α and peroxisome proliferator− activated receptor-δ. Elafibranor improves insulin …

Obesity is a worldwide epidemic that predisposes individuals to cardiometabolic
complications, such as type 2 diabetes mellitus (T2DM) and nonalcoholic fatty liver disease …

Peroxisome proliferator-activated receptor α (PPARα) is a ligand-activated transcription
factor belonging, together with PPARγ and PPARβ/δ, to the NR1C nuclear receptor …

Given the high prevalence and rising incidence of non-alcoholic fatty liver disease (NAFLD),
the absence of approved therapies is striking. Although the mainstay of treatment of NAFLD …

The occurrence of nonalcoholic fatty liver disease (NAFLD) is associated with major
abnormalities of hepatic lipid metabolism. We propose that lipid abnormalities directly or …